Single-dose intrapulmonary pharmacokinetics of azithromycin, clarithromycin, ciprofloxacin, and cefuroxime in volunteer subjects

Antimicrobial Agents and Chemotherapy

Volumn 40, Issue 7, 1996, Pages 1617-1622

  Conte Jr , John E ^a   Golden, Jeff ^a   Duncan, Sheila ^a   McKenna, Elaine ^a   Lin, Emil ^a   Zurlinden, Elisabeth ^a  

^a UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

14 HYDROXYCLARITHROMYCIN; ANTIBIOTIC AGENT; AZITHROMYCIN; CEFOXITIN; CEFUROXIME; CIPROFLOXACIN; CLARITHROMYCIN;

ADULT; ANTIBIOTIC THERAPY; AREA UNDER THE CURVE; ARTICLE; BRONCHOSCOPY; CLINICAL TRIAL; CONCENTRATION RESPONSE; DRUG ABSORPTION; DRUG EFFICACY; DRUG PENETRATION; DRUG TISSUE LEVEL; FEMALE; HUMAN; HUMAN CELL; HUMAN EXPERIMENT; HUMAN TISSUE; LUNG ALVEOLUS CELL; LUNG ALVEOLUS EPITHELIUM; LUNG LAVAGE; MALE; NORMAL HUMAN; ORAL DRUG ADMINISTRATION; PRIORITY JOURNAL;

EID: 0029889732     PISSN: 00664804     EISSN: None     Source Type: Journal    
DOI: 10.1128/aac.40.7.1617     Document Type: Article

References (45)

1. Anderson, R., G. Joone, and C. E. van Rensburg. 1988. An in vitro evaluation of the cellular uptake and intraphagocytic bioactivity of clarithromycin (A-56268, TE-031), a new macrolide antimicrobial agent. J. Antimicrob. Chemother. 22:923-933.
2. Baldwin, D. R., J. M. Andrews, R. Wise, and D. Honeybourne. 1992. Bronchoalveolar distribution of cefuroxime axetil and in-vitro efficacy of observed concentrations against respiratory pathogens. J. Antimicrob. Chemother. 30: 377-385.
3. Baldwin, D. R., R. Wise, J. M. Andrews, J. P. Ashby, and D. Honeybourne. 1990. Azithromycin concentrations at the sites of pulmonary infection. Eur. Respir. J. 3:886-890.
4. Baldwin, D. R., R. Wise, J. M. Andrews, M. Gill, and D. Honeybourne. 1993. Comparative bronchoalveolar concentrations of ciprofloxacin and lomefloxacin following oral administration. Respir. Med. 87:595-601.
5. Bingen, E., C. Doit, R. Farinotti, and N. Lambert-Zechovsky. 1993. Killing kinetics of cefuroxime against Streptococcus pneumoniae in an in vitro model simulating serum concentration profiles after intramuscular administration. Eur. J. Clin. Microbiol. Infect. Dis. 12:297-299.
6. Bonnet, M., and P. Van der Auwera. 1992. In vitro and in vivo intraleukocytic accumulation of azithromycin (CP-62, 993) and its influence on ex vivo leukocyte chemiluminescence. Antimicrob. Agents Chemother. 36:1302-1309.
7. Catchpole, C., J. M. Andrews, J. Woodcock, and R. Wise. 1994. The comparative pharmacokinetics and tissue penetration of single-dose ciprofloxacin 4(10 mg IV and 750 mg p.o. J. Antimicrob. Chemother. 33:103-110.
8. Chu, S. Y., L. T. Sennello, S. T. Bunnell, L. L. Varga, D. S. Wilson, and R. C. Sonders. 1992. Pharmacokinetics of clarithromycin, a new macrolide, after single ascending oral doses. Antimicrob. Agents Chemother. 36:2447-2453.
9. Chu, S. Y., L. T. Sennello, and R. C. Sonders. 1991. Simultaneous determination of clarithromycin and 14(R)-hydroxyclarithromycin in plasma and urine using high-performance liquid chromatography with electrochemical detection. J. Chromatogr. 571:199-208.
10. Chu, S. Y., D. S. Wilson, D. R. Guay, and C. Craft. 1992. Clarithromycin pharmacokinetics in healthy young and elderly volunteers. J. Clin. Pharmacol. 32:1045-1049.
11. Cohen, Y., C. Perronne, C. Truffot-Pernot, J. Grosset, J. L. Vilde, and J. J. Pocidalo. 1992. Activities of WIN-57273, minocyeline, clarithromycin, and 14-hydroxy-clarithromycin against Mycobacterium avium complex in human macrophages. Antimicrob. Agents Chemother. 36:2104-2107.
12. Conte, J. E., Jr., J. A. Golden, S. Duncan, E. McKenna, and E. Zurlinden. 1995. Intrapulmonary pharmacokinetics of clarithromycin and of erythromycin. Antimicrob. Agents Chemother. 39:334-338.
13. Donowitz, G. R., and K. I. Earnhardt. 1993. Azithromycin inhibition of intracellular Legionella micdadei. Antimicrob. Agents Chemother. 37:2261-2264.
14. Ettensohn, D. B., M. J. Jankowski, A. A. Redondo, and P. G. Duncan. 1988. Bronchoalveolar lavage in the normal volunteer subject. Part 2. Safety and results of repeated BAL and use in the assessment of intrasubject variability. Chest 94:281-285.
15. Fitzgeorge, R. B., S. Lever, and A. Baskerville. 1993. A comparison of the efficacy of azithromycin and clarithromycin in oral therapy of experimental airborne Legionnaires' disease. J. Antimicrob. Chemother. 34:171-176.
16. Gisby, J., B. J. Wightman, and A. S. Beale. 1991. Comparative efficacies of ciprofloxacin amoxicillin, amoxicillin-clavulanic acid, and cefaclor against experimental Streptococcus pneumoniae respiratory infections in mice. Antimicrob. Agents Chemother. 35:831-836.
17. Hammerschlag, M. R., K. K. Qumei, and P. M. Roblin. 1992. In vitro activities of azithromycin, clarithromycin, L-ofloxacin, and other antibiotics against Chlamydia pneumoniae. Antimicrob. Agents Chemother. 36:1573-1574.
18. Hoepelman, A. I., A. P. Sips, J. L. van Helmond, P. W. van Barneveld, A. J. Neve, M. Zwinkels, M. Rozenberg-Arska, and J. Verhoef. 1993. A single-blind comparison of three-day azithromycin and ten-day co-amoxiclav treatment of acute lower respiratory tract infections. J. Antimicrob. Chemother. 31(Suppl. E):147-152.
19. Holford, N. H. G. 1982. DRUGMODEL, p. 1-14. In H. M. Perry (ed.), Public procedures notebook, suppl. I. Bolt Beranek and Newman. Cambridge, Mass.
20. Honeybourne, D., and D. R. Baldwin. 1992. The site concentrations of antimicrobial agents in the lung. J. Antimicrob. Chemother. 30:249-260.
21. Honeybourne, D., F. Kees, J. M. Andrews, D. Baldwin, and R. Wise. 1994. The levels of clarithromycin and its 14-hydroxy-metabolite in the lung. Eur. Respir. J. 7:1275-1280.
22. Israel, D., J. G. Gillum, M. Turik, K. Harvey, J. Ford, H. Dalton, M. Towle, R. Echols, A. H. Heller, and R. Polk. 1993. Pharmacokinetics and serum bactericidal titers of ciprofloxacin and ofloxacin following multiple oral doses in healthy volunteers. Antimicrob. Agents Chemother. 37:2193-2199.
23. James, N. C., K. H. Donn, J. J. Collins, I. M. Davis, T. L. Lloyd, R. W. Hart, and J. R. Powell. 1991. Pharmacokinelics of cefuroxime axetil and cefactor: relationship of concentrations in serum to MICs for common respiratory pathogens. Antimicrob. Agents Chemother. 35:1860-1863.
24. Konishi, K., H. Suzuki, M. Hayashi, and T. Saruta. 1993. Pharmacokinetics of cefuroxime axetil in patients with normal and impaired renal function. J. Antimicrob. Chemother. 31:413-4211.
25. Krol, G. J. 1986. Liquid chromatography analysis of ciprofloxacin and ciprofloxacin metabolites in body fluids. J. Liquid Chromatogr. 9:2897-2919.
26. Lalak, N. J., and D. L. Morris. 1993. Azithromycin clinical pharmacokinetics. Clin. Pharm. 25:370-374.
27. Lee, B. L., A. M. Padula, R. C. Kimbrough, S. R. Jones, R. E. Chaisson, J. Mills, and M. A. Sande. 1991. Infectious complications with respiratory pathogens despite ciprofloxacin therapy. N. Engl. J. Med. 325:520-521. (Letter.)
28. Loos, U., and F. Kees. 1991. Bronchopulmonary disposition of clarithromycin, abstr. 441. In Proceedings of the 17th International Congress of Chemotherapy. University Hospital of Bonn, Bonn, and University of Regensburg, Regensburg, Germany.
29. Merchant, R. K., D. A. Schwartz, R. A. Helmers, C. S. Dayton, and G. W. Hunninghake. 1992. Bronchoalveolar lavage cellularity: the distribution in normal volunteers. Am. Rev. Respir. Dis. 146:448-453.
30. Metropolitan Life Insurance Company. 1983. 1983 Metropolitan height and weight tables. Stat. Bull. 64:2-9.
31. Meyer, A. P., C. Bril-Bazuin, H. Mattie, and P. J. van den Broek. 1993. Uptake of azithromycin by human monocytcs and enhanced intracellular antibacterial activity against Staphylococcus aureus. Antimicrob. Agents Chemother. 37:2318-2322.
32. National Center for Research Resources, National Institutes of Health. 1990. PROPHET statistics, p. 18-20, 57-61, and 95-103. National Institutes of Health, Bethesda, Md.
33. Paniara, O., E. Platsouka, H. Dimopoulou, and S. Constantoulaki. 1994. In vitro evaluation of cefodizime, cefuroxime, and ceftriaxone against respiratory pathogens. J. Chemother. 6:35-38.
34. Peters, D. H., H. A. Friedel, and D. McTavish. 1992. Azithromycin: a review of its antimicrobial activity, pharmacokinetic properties and clinical efficacy. Drugs 44:750-799.
35. Rastogi, N., K. S. Goh, and V. Labrousse. 1992. Activity of clarithromycin compared with those of other drugs against Mycobacterium paratuberculosis and further enhancement of its extracellular and intracellular activities by ethambutol. Antimicrob. Agents Chemother. 36:2843-2846.
36. Rennard, S. I., G. Basset, D. Lecossier, K. M. O'Donnell, P. Pinkston, P. G. Martin, and R. G. Crystal. 1986. Estimation of volume of epithelial lining fluid recovered by lavage using urea as a marker of dilution. J. Appl. Physiol. 60:532-538.
37. Ritchie, D. J., A. W. Hopefl, T. W. Milligan, J. E. Byrne, and M. S. Maddux. 1993. In vitro activity of clarithromycin, cefprozil, and other common oral antimicrobial agents against gram-positive and gram-negative pathogens. Clin. Ther. 15:107-113.
38. Scaglione, F., G. Demartini, S. Dugnani, and F. Fraschini. 1993. A new model examining intracellular and extracellular activity of amoxicillin, azithromycin, and clarithromycin in infected cells. Chemotherapy (Basel) 39: 416-423.
39. Shepard, R. M. 1991. HPLC assay with electrochemical detector for azithromycin in serum and tissues. J. Chromatogr. 565:321-337.
40. Talke, H., and G. E. Schubert. 1965. Enzymatische Harnstoffbestimmung im Blut und Serum im optischem Test nach Warburg. Klin. Wochschr. 43:174.
41. Wilcox, M., A. Kervitsky, L. C. Watters, and T. E. King, Jr. 1988. Quantification of cells recovered by bronchoalveolar lavage. Am. Rev. Respir. Dis. 138:74-80.
42. Wildfeuer, A., H. Laufen, M. Leitold, and T. Zimmerman. 1993. Comparison of the pharmacokinetics of three-day and five-day regimens azithromycin in plasma and urine. J. Antimicrob. Chemother. 31(Suppl. E):51-56.
43. Williams, J. D., J. P. Maskel, H. Shain, G. Chrysos, A. M. Sefton, H. Y. Fraser, and J. M. Hardie. 1992. Comparative in-vitro activity of azithromycin, macrolides (erythromycin, clarithromycin and spiramycin) and streptogramin RP 59500 against oral organisms. J. Anlimicrob. Chemother. 30: 27-37.
44. Wise, R., S. A. Bennett, and J. Dent. 1984. The pharmacokinetics of orally absorbed cefuroxime compared with amoxycillin/clavulanic acid. J. Antimicrob. Chemother. 13:603-610.
45. Zar, J. H. 1984. Multisample hypotheses: the analysis of variance. Multiple comparisons, p. 162-205. In Biostatistical analysis, 2nd ed. Prentice-Hall, Englewood Cliffs, N.J.